Literature DB >> 24082383

Ventricular fibrillation cardiac arrest due to 5-fluorouracil cardiotoxicity.

Michael G Fradley1, Conor D Barrett, John R Clark, Sanjeev A Francis.   

Abstract

The antimetabolite chemotherapeutic agent 5-fluorouracil is used to treat a variety of cancers. Although 5-fluorouracil is generally well tolerated, its toxicity profile includes potential cardiac ischemia, vasospasm, arrhythmia, and direct myocardial injury. These actual or potential toxicities are thought to resolve upon cessation of the medication; however, information about the long-term cardiovascular effects of therapy is not sufficient. We present the case of a 58-year-old man who had 2 ventricular fibrillation cardiac arrests, with evidence of coronary vasospasm and myocarditis, on his 4th day of continuous infusion with 5-fluorouracil. External defibrillation and cessation of the 5-fluorouracil therapy resolved the patient's electrocardiographic abnormalities. In addition to reporting the clinical manifestations of 5-fluorouracil-associated cardiotoxicity in our patient, we discuss management challenges in patients who develop severe 5-fluorouracil-induced ventricular arrhythmias.

Entities:  

Keywords:  Arrhythmias, cardiac/chemically induced; coronary vasospasm/chemically induced; fluorouracil/adverse effects; heart diseases/drug therapy; heart/drug effects; myocarditis/chemically induced; treatment outcome

Mesh:

Substances:

Year:  2013        PMID: 24082383      PMCID: PMC3783134     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  21 in total

Review 1.  ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary.

Authors:  Andrew E Epstein; John P Dimarco; Kenneth A Ellenbogen; N A Mark Estes; Roger A Freedman; Leonard S Gettes; A Marc Gillinov; Gabriel Gregoratos; Stephen C Hammill; David L Hayes; Mark A Hlatky; L Kristin Newby; Richard L Page; Mark H Schoenfeld; Michael J Silka; Lynne Warner Stevenson; Michael O Sweeney
Journal:  Heart Rhythm       Date:  2008-05-19       Impact factor: 6.343

2.  Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease.

Authors:  Panayota Tsibiribi; Jacques Descotes; Catherine Lombard-Bohas; Cécile Barel; Bernard Bui-Xuan; Majda Belkhiria; Alain Tabib; Quadiri Timour
Journal:  Bull Cancer       Date:  2006-03-01       Impact factor: 1.276

3.  Letter: 5-Fluorouracil and angina.

Authors:  R G Dent; I McColl
Journal:  Lancet       Date:  1975-02-08       Impact factor: 79.321

4.  Cardiotoxicity of 5-fluorouracil.

Authors:  D L Stevenson; D P Mikhailidis; D S Gillett
Journal:  Lancet       Date:  1977-08-20       Impact factor: 79.321

5.  Cardiac lesions induced by 5-fluorouracil in the rabbit.

Authors:  P Tsibiribi; C Bui-Xuan; B Bui-Xuan; C Lombard-Bohas; S Duperret; M Belkhiria; A Tabib; G Maujean; J Descotes; Q Timour
Journal:  Hum Exp Toxicol       Date:  2006-06       Impact factor: 2.903

Review 6.  The spectrum of 5-fluorouracil cardiotoxicity.

Authors:  Jonathan R Dalzell; Leslie M Samuel
Journal:  Anticancer Drugs       Date:  2009-01       Impact factor: 2.248

7.  Cardiovascular magnetic resonance in myocarditis: A JACC White Paper.

Authors:  Matthias G Friedrich; Udo Sechtem; Jeanette Schulz-Menger; Godtfred Holmvang; Pauline Alakija; Leslie T Cooper; James A White; Hassan Abdel-Aty; Matthias Gutberlet; Sanjay Prasad; Anthony Aletras; Jean-Pierre Laissy; Ian Paterson; Neil G Filipchuk; Andreas Kumar; Matthias Pauschinger; Peter Liu
Journal:  J Am Coll Cardiol       Date:  2009-04-28       Impact factor: 24.094

8.  Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD.

Authors:  Arthur M Feldman; Helmut Klein; Patrick Tchou; Srinivas Murali; W Jackson Hall; Donna Mancini; John Boehmer; Mark Harvey; M Stephen Heilman; Steven J Szymkiewicz; Arthur J Moss
Journal:  Pacing Clin Electrophysiol       Date:  2004-01       Impact factor: 1.976

9.  5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators.

Authors:  B Patel; R A Kloner; J Ensley; M Al-Sarraf; J Kish; J Wynne
Journal:  Am J Med Sci       Date:  1987-10       Impact factor: 2.378

10.  Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience.

Authors:  W Gradishar; E Vokes; R Schilsky; R Weichselbaum; W Panje
Journal:  Med Pediatr Oncol       Date:  1991
View more
  4 in total

Review 1.  QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics.

Authors:  Sanjay Chandrasekhar; Michael G Fradley
Journal:  Curr Treat Options Oncol       Date:  2019-05-25

2.  Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study.

Authors:  Merete Vaage-Nilsen; Dorte L Nielsen; Anne Dyhl-Polk; Morten Schou; Kirsten K Vistisen; Anne-Sophie Sillesen; Eva Serup-Hansen; Jens Faber; Tobias W Klausen; Stig E Bojesen
Journal:  Oncologist       Date:  2020-10-07

Review 3.  Electrophysiologic Toxicity of Chemoradiation.

Authors:  Merna A Armanious; Shreya Mishra; Michael G Fradley
Journal:  Curr Oncol Rep       Date:  2018-04-11       Impact factor: 5.075

4.  Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients' heart?

Authors:  Caterina Fontanella; Marianna Aita; Marika Cinausero; Giuseppe Aprile; Maria Grazia Baldin; Veronica Dusi; Chiara Lestuzzi; Gianpiero Fasola; Fabio Puglisi
Journal:  Onco Targets Ther       Date:  2014-09-29       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.